Holen Sie sich die Stockscreener-App
4.87
9.68%
0.43
Handel nachbörslich:
4.86
-0.010
-0.21%
Schlusskurs vom Vortag:
$4.44
Offen:
$4.45
24-Stunden-Volumen:
4.15M
Relative Volume:
0.94
Marktkapitalisierung:
$1.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-283.26M
KGV:
-3.3129
EPS:
-1.47
Netto-Cashflow:
$-273.61M
1W Leistung:
+16.51%
1M Leistung:
+86.59%
6M Leistung:
+39.14%
1J Leistung:
-20.29%
1-Tages-Spanne:
$4.33
$4.89
1-Wochen-Bereich:
$4.0912
$4.89
52-Wochen-Spanne:
$1.26
$7.30
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Vergleichen Sie SANA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
4.87 | 942.82M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-03-18 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-11-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
Sana Biotechnology Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
Is Sana Biotechnology Inc. a good long term investmentFree Trading Strategy Suggestions - jammulinksnews.com
What analysts say about Sana Biotechnology Inc. stockBreakout portfolio performance - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results - MSN
Commit To Purchase Sana Biotechnology At $2.50, Earn 28% Using Options - Nasdaq
What drives Sana Biotechnology Inc. stock priceMassive profits - jammulinksnews.com
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley - MSN
Sana Biotechnology (SANA) Soars 4.11% on Positive Diabetes Data - AInvest
Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting - MSN
Sana Biotechnology’s SWOT analysis: innovative cell therapy stock faces challenges By Investing.com - Investing.com South Africa
Sana Biotechnology’s SWOT analysis: innovative cell therapy stock faces challenges - Investing.com
Sana Biotechnology's 9% Spike: Technical Signals and Peer Dynamics Drive Unusual Intraday Rally - AInvest
Sana Biotechnology (SANA.O) Surges 9% Amid Technical Bullish Signal: What’s Driving the Move? - AInvest
Sana Biotechnology's 9% Surge: Technical Bullishness or Biotech Momentum? - AInvest
Sana Biotechnology's 9% Surge: Technical Bullish Signal or Sector Shift? - AInvest
Sana Biotechnology’s 9% Surge: Technical Catalysts and Peer Dynamics - AInvest
Sana Biotechnology's 9% Surge: Technicals or a Hidden Catalyst? - AInvest
Sana Biotechnology's 9% Spike: A Technical Catalyst Amid Mixed Biotech Sentiment - AInvest
Sana Biotechnology's 9% Surge: Technical Catalysts and Market Dynamics - AInvest
Sana Biotechnology assumed with an Overweight at Morgan Stanley - TipRanks
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Sana Biotechnology, Inc.(NasdaqGS: SANA) added to Russell 3000E Value Index - MarketScreener
Sana Biotechnology (SANA) Receives a Buy from Citizens JMP - The Globe and Mail
BofA Remains Bullish on Sana Biotechnology (SANA) - MSN
Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes - Nasdaq
SANA Stock on the Rise: A Promising Investment - investchronicle.com
Investigation announced for long-term Investors in shares - openPR.com
Pallas Capital Advisors LLC Makes New $29,000 Investment in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology (NASDAQ:SANA) versus Mosaic ImmunoEngineering (OTCMKTS:CPMV) Critical Analysis - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 25,383 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Lead Plaintiff Appointed in Sana Biotechnology Class Action — Here’s How You Can Recover Your Losses - TradingView
Paysign Leads Our Trio Of Penny Stock Highlights - simplywall.st
Transcript : Sana Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Sana Biotechnology to present at 85th annual American Diabetes Association Scientific Sessions - marketscreener.com
Sana Biotechnology to Present First-in-Human Clinical Data on Hypoimmune Islet Cell Therapy for Type 1 Diabetes at ADA Scientific Sessions - Nasdaq
Sana Biotechnology Announces Invited Oral Presentation at - GlobeNewswire
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes ... - Bluefield Daily Telegraph
Sana Bio to Present Novel Immunosuppression-Free Diabetes Cell Therapy Data at ADA | SANA Stock News - Stock Titan
Shareholders Filed a Lawsuit Against $SANA for Misleading Investors About Financial Health - TradingView
Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):